Tag: Feiba

FEIBA is a sterile, freeze-dried human plasma fraction manufactured from large pools of human plasma. This article delves into the key question: what is FEIBA made of and how do its components work to control bleeding in patients with hemophilia and inhibitors?

When managing severe bleeding, clinicians must often rapidly reverse the effects of anticoagulants, which is where agents like Kcentra and FEIBA play a critical role. Understanding what is the difference between Kcentra and FEIBA is vital, as these human plasma-derived concentrates serve different primary indications due to their unique compositions.

Feiba, also known as Anti-inhibitor Coagulant Complex, has a history of over 30 years of use in controlling bleeding episodes in hemophilia patients who have developed inhibitors. Specifically, **what is the use of Feiba injection?** It is a crucial therapeutic option for those with hemophilia A or B who have developed antibodies (inhibitors) against their standard clotting factor treatments, making those therapies ineffective. Feiba works by bypassing the inhibited factor to restore the blood clotting process and stop bleeding.

In clinical trials, Feiba was effective in managing 88% to 93% of bleeding episodes in patients with hemophilia and inhibitors. **What is Feiba?** It is an Anti-Inhibitor Coagulant Complex used to control and prevent bleeding in these specific patient populations.